RADX (Radiopharm Theranostics Limited American Depositary Shares) Stock Analysis - AI Report

Radiopharm Theranostics Limited American Depositary Shares (RADX) is a publicly traded Healthcare sector company. As of May 21, 2026, RADX trades at $4.58 with a market cap of $37.45M and a P/E ratio of 0.00. RADX moved -0.22% today. Year to date, RADX is -10.20%; over the trailing twelve months it is +4.09%. Its 52-week range spans $3.50 to $50.82. Analyst consensus is buy with an average price target of $22.50. Rallies surfaces RADX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the AI research view on RADX?

Rallies AI research for RADX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.

RADX Key Metrics

Key financial metrics for RADX
MetricValue
Price$4.58
Market Cap$37.45M
P/E Ratio0.00
EPS$0.00
Dividend Yield0.00%
52-Week High$50.82
52-Week Low$3.50
Volume112
Avg Volume0
Revenue (TTM)$0
Net Income$0
Gross Margin0.00%

Latest RADX News

RADX Analyst Consensus

2 analysts cover RADX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $22.50.

Common questions about RADX

What is the AI research view on RADX?
Rallies AI research for RADX combines live market data, fundamentals, news, analyst context, hedge fund holdings, politician trades, insider activity, and risk factors into a ticker-specific research workflow.
What data powers the Rallies AI report for RADX?
Rallies AI research for RADX combines live market data, financials, news, analyst context, hedge fund ownership, politician disclosures, insider activity, and risk factors.
Is RADX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for RADX. It does not provide personalized investment advice.
RADX

RADX